Although intensive researches have comprehensively described the roles of aberrant SPOP mutations or expressions on kidney cancer, prostate cancer and endometrial cancer, the specific roles of SPOP on hematologic tumors are still unclear [25, 50]. This evidence concerns the gene SPOP and Familial prostate cancer.